Risk Assessment of BRONJ in Oncologic Patients Treated with Bisphosphonates: Follow-Up to 18 Months

Table 4

Risk evaluation to T0 (bold = high risk, italic = low risk, and bold italic = not definable risk).

P. 1

P.2

P.3

P.4

P.5

P.6

P.7

P.8

P.9

P.10

Aminobisphosphonates molecule

Zoledronate

X

X

X

X

X

X

X

X

Not changeable risk factors

Ibandronate

X

X

Other medicines/therapies

Subsequent chemotherapy

X

X

Subsequent radiotherapy

X

X

X

X

Concomitant corticosteroids administration

X

X

Administration

Intravenous

X

X

X

X

X

X

X

X

Oral

X

X

Systemic factors

Presence of cancer

X

X

X

X

X

X

X

X

X

X

Local risk factors

Periodontal pathology

X

X

X

X

X

X

X

Modifiable risk factors

Dental pathology

X

X

X

X

X

X

X

X

X